Completion of Acquisitions and Re-Admission

Summary by AI ^BETAClose X

Vulcan Two Group plc has successfully completed the acquisition of CloudRx, Hyperdrug, and Webmed, and has raised £40 million through an institutional Placing. Following shareholder approval, the company's Ordinary Shares were re-admitted to trading on AIM this morning. The total issued share capital now stands at 27,275,000 Ordinary Shares, and Keith Butcher has joined the Board of Directors.

Disclaimer*

Vulcan Two Group PLC

19 March 2026

Vulcan Two Group plc

(the "Company")

Completion of Acquisitions,

Completion of Placing and

Re-admission to trading

Vulcan Two Group plc, the company aiming to create the UK's leading regulated ePharmacy through buy-and-build, is pleased to announce that, further to the announcement on 26 February 2026 (the "Launch Announcement"), it has now completed the acquisition of CloudRx, Hyperdrug and Webmed (the "Targets"). The Company has also completed an institutional Placing for £40 million, the detail of which was included in the Launch Announcement.

The acquisition of the Targets, individually and collectively, constituted a Reverse Takeover pursuant to Rule 14 of the AIM Rules for Companies. Accordingly, having received shareholder approval at a General Meeting on 17 March 2026, the Company's existing Ordinary Shares were re-admitted to trading on AIM at 8.00 a.m. this morning, alongside the new Ordinary Shares issued pursuant to the Placing and the Acquisitions ("Re-admission").

Directorate Changes

As set out in the Launch Announcement, Keith Butcher has been appointed to the Company's Board of Directors with effect from Re-admission.

Total Voting Rights

Following Re-admission, the Company's total issued share capital now consists of 27,275,000 Ordinary Shares. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Other than where defined, capitalised terms used in this announcement have the meanings given to them in the Launch Announcement.

For further information please contact:

Vulcan Two Group plc

Michael Kraftman, Chief Executive Officer

Brendan O'Brien, Chief Operating Officer

Keith Butcher, Chief Financial Officer

www.vulcantwo.com

Email: info@vulcantwo.com

Canaccord Genuity Limited
(Nominated Adviser and Sole Broker)

Simon Bridges / Harry Pardoe / Elizabeth Halley-Stott

Tel: +44 (0) 20 7523 8000

Alma Strategic Communications
(Financial PR)

Justine James / Sam Modlin / Will Merison

Email: vulcantwo@almastrategic.com

Tel: +44 (0) 20 3405 0205

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END